Background: Although clopidogrel is still frequently used in patients with acute coronary
syndromes (ACS), its efficacy is hampered by interpatient response variability caused by …

Background Pharmacogenetic determinants of the response of patients to clopidogrel
contribute to variability in the biologic antiplatelet activity of the drug. The effect of these …

Summary Background: The CYP2C19 genotype is a predictor of adverse cardiovascular
events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary …

Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute
coronary syndromes, ticagrelor reduced the composite outcome of cardiovascular death …

Aims Clopidogrel is prescribed for the prevention of atherothrombotic events. While
investigations have identified genetic determinants of inter-individual variability in on …

Background Clopidogrel has provided beneficial effects in acute coronary syndrome and
percutaneous coronary intervention. Different polymorphisms have been associated with …

The widespread use of clopidogrel alone or in combination with aspirin has significantly
benefited patients with acute coronary syndrome who are managed medically or by …

Current guidelines recommend dual antiplatelet therapy—a P2Y12 inhibitor (clopidogrel,
prasugrel, or ticagrelor) and aspirin—for patients undergoing percutaneous coronary …

Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated
with adverse clinical outcomes. CYP2C19 loss‐of‐function alleles play an important role in …